Cabaletta Bio Inc
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immu… Read more
Cabaletta Bio Inc (CABA) - Net Assets
Latest net assets as of September 2025: $139.47 Million USD
Based on the latest financial reports, Cabaletta Bio Inc (CABA) has net assets worth $139.47 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($189.76 Million) and total liabilities ($50.29 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $139.47 Million |
| % of Total Assets | 73.5% |
| Annual Growth Rate | N/A |
| 5-Year Change | 39.06% |
| 10-Year Change | N/A |
| Growth Volatility | 58.11 |
Cabaletta Bio Inc - Net Assets Trend (2017–2024)
This chart illustrates how Cabaletta Bio Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cabaletta Bio Inc (2017–2024)
The table below shows the annual net assets of Cabaletta Bio Inc from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $152.34 Million | -35.51% |
| 2023-12-31 | $236.20 Million | +125.98% |
| 2022-12-31 | $104.52 Million | -11.39% |
| 2021-12-31 | $117.96 Million | +7.68% |
| 2020-12-31 | $109.54 Million | -20.80% |
| 2019-12-31 | $138.32 Million | +1393.93% |
| 2018-12-31 | $-10.69 Million | -4193.17% |
| 2017-12-31 | $-249.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cabaletta Bio Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 34885100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | 0.00% |
| Other Components | $501.44 Million | 329.17% |
| Total Equity | $152.34 Million | 100.00% |
Cabaletta Bio Inc Competitors by Market Cap
The table below lists competitors of Cabaletta Bio Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Fujian Raynen Tech Co Ltd
SHG:603933
|
$220.06 Million |
|
Probe Metals Inc
OTCQB:PROBF
|
$220.06 Million |
|
Oxford Biomedica plc
PINK:OXBDF
|
$220.17 Million |
|
Vigil Neuroscience Inc
NASDAQ:VIGL
|
$220.17 Million |
|
Zhang Jia Jie Tourism Group Co Ltd
SHE:000430
|
$220.00 Million |
|
Entrada Therapeutics Inc
NASDAQ:TRDA
|
$220.00 Million |
|
Shanghai Flyco Electrical Appliance Co Ltd
SHG:603868
|
$219.92 Million |
|
Hextar Global Bhd
KLSE:5151
|
$219.90 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cabaletta Bio Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 236,198,000 to 152,335,000, a change of -83,863,000 (-35.5%).
- Net loss of 115,864,000 reduced equity.
- Share repurchases of 269,000 reduced equity.
- New share issuances of 10,875,000 increased equity.
- Other comprehensive income decreased equity by 39,000.
- Other factors increased equity by 21,434,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-115.86 Million | -76.06% |
| Share Repurchases | $269.00K | -0.18% |
| Share Issuances | $10.88 Million | +7.14% |
| Other Comprehensive Income | $-39.00K | -0.03% |
| Other Changes | $21.43 Million | +14.07% |
| Total Change | $- | -35.51% |
Book Value vs Market Value Analysis
This analysis compares Cabaletta Bio Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.01x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-0.01 | $3.10 | x |
| 2018-12-31 | $-0.74 | $3.10 | x |
| 2019-12-31 | $25.29 | $3.10 | x |
| 2020-12-31 | $4.73 | $3.10 | x |
| 2021-12-31 | $4.58 | $3.10 | x |
| 2022-12-31 | $3.56 | $3.10 | x |
| 2023-12-31 | $5.77 | $3.10 | x |
| 2024-12-31 | $3.08 | $3.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cabaletta Bio Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -76.06%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.21x
- Recent ROE (-76.06%) is below the historical average (-29.18%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-225.10K |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-11.13 Million |
| 2019 | -10.92% | 0.00% | 0.00x | 1.02x | $-28.93 Million |
| 2020 | -29.66% | -324910000000.00% | 0.00x | 1.05x | $-43.45 Million |
| 2021 | -38.60% | 0.00% | 0.00x | 1.07x | $-57.33 Million |
| 2022 | -49.57% | 0.00% | 0.00x | 1.12x | $-62.26 Million |
| 2023 | -28.65% | 0.00% | 0.00x | 1.07x | $-91.29 Million |
| 2024 | -76.06% | 0.00% | 0.00x | 1.21x | $-131.10 Million |
Industry Comparison
This section compares Cabaletta Bio Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cabaletta Bio Inc (CABA) | $139.47 Million | 0.00% | 0.36x | $220.04 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |